New research shows that intensive bisphosphonate therapy for Paget disease of bone has no beneficial effect on quality of life, bone pain or clinical complications compared with symptomatic management. What are the implications of these findings on the management of patients with Paget disease?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Langston, A. L. et al. Randomised trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J. Bone Miner. Res. doi:10.1359/JBMR.090709.
Siris, E. S. Goals of treatment for Paget's disease of bone. J. Bone Miner. Res. 14 (Suppl. 2), 49–52 (1999).
Selby, P. L., Davie, M. W. J., Ralston, S. H. & Stone, M. D. Guidelines on the management of Paget's disease of bone. Bone 31, 366–373 (2002).
Wermers, R. A., Tiegs, R. D., Atkinson, E. J., Achenbach, S. J. & Melton, L. J. 3rd. Morbidity and mortality associated with Paget's disease of bone: a population-based study. J. Bone Miner. Res. 23, 819–825 (2008).
Miller, P. D. et al. A comparative trial of risedronate versus etidronate in the treatment of patients with Paget's disease of bone. Am. J. Med. 106, 513–520 (1999).
Reid, I. R. et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353, 898–908 (2005).
Josse, R. G. et al. Diagnosis and treatment of Paget's disease of bone. Clin. Invest. Med. 30, E210–E223 (2007).
Meunier, P. J. & Vignon, E. Therapeutic strategy in Paget's disease of bone. Bone 17, S489–S491 (1999).
Altman, R. D. et al. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N. Engl. J. Med. 289, 1379–1384 (1973).
Fraser, W. D., Stamp, T. C., Creek, R. A., Sawyer, J. P. & Picot, C. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad. Med. J. 73, 496–502 (1997).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr. Brown reports has received honoraria for lecturing and consultancies, as well as grants and research support for running clinical trials, from the following companies: Abbott, Amgen, Arthrolab, Bristol-Myers Squibb, Eli Lilly Canada, Glaxosmithkline, Merck Frosst, Novartis, Nycomed, Pfizer, Procter & Gamble, Roche, Sanofi-Aventis Canada, Servier, and Wyeth.
Rights and permissions
About this article
Cite this article
Brown, J. Treating Paget disease: when matters more than how. Nat Rev Rheumatol 5, 663–665 (2009). https://doi.org/10.1038/nrrheum.2009.230
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.230
